Related Experiment Videos
Is the indirect antiglobulin crossmatch justified?
D M Peterson1, D J Roxby, R Seshadri
1Department of Haematology, Flinders Medical Centre, Bedford Park, South Australia.
Pathology
|April 1, 1987
Summary
Omitting antiglobulin crossmatch testing after a negative red blood cell antibody screen is safe and improves transfusion efficiency. This streamlines laboratory processes and reduces costs without compromising patient safety.
Area of Science:
- Transfusion Medicine
- Clinical Pathology
- Immunohaematology
Background:
- Pretransfusion testing aims to ensure transfusion safety and efficiency.
- Current practices debate the necessity of antiglobulin crossmatching when antibody screens are negative.
Purpose of the Study:
- To evaluate the clinical significance of antibodies detected solely by antiglobulin crossmatch.
- To assess the impact of omitting antiglobulin crossmatch on patient safety and laboratory efficiency.
Main Methods:
- Retrospective analysis of pretransfusion testing data.
- Identification of antibody specificities and clinical relevance found only during crossmatch.
Main Results:
- Antibodies detected exclusively by antiglobulin crossmatch showed no significant clinical impact.
- Omission of antiglobulin crossmatch does not compromise patient safety.
- Significant cost savings for laboratories due to reduced reagent use and processing time.
Conclusions:
- Antiglobulin crossmatch can be safely omitted when antibody screens are negative.
- Reallocating cost savings to patient identification systems and autologous blood services can enhance safety.
- Streamlined pretransfusion testing improves efficiency and reduces healthcare costs.